EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome
Medicine should no longer be used for other disorders of the gut
A review by the European Medicines Agency (EMA) has concluded that Symbioflor 2 and associated names can continue to be used for treatment of irritable bowel syndrome (IBS) in adults. However, the medicine should no longer be used more widely to treat so-called functional gastrointestinal disorders, a group of disorders with a variety of causes that may require different treatment approaches.
Symbioflor 2, which contains Escherichia coli bacteria, has been described as a probiotic, which means that it encourages the growth of beneficial organisms (‘flora’) in the gut. It was first made available in Germany in the 1950s and subsequently in Austria and Hungary.
In reaching its conclusions, EMA’s Committee for Medicinal Products for Human Use(CHMP) reviewed all available evidence on the effectiveness and safety of Symbioflor 2. The data included clinical studies, scientific publications, post-marketing experience, as well as information provided by the company and the views of an expert group formed for evaluating Symbioflor 2. The review did not find any new evidence on the effectiveness of Symbioflor 2 since the product was last approved. Available evidence suggests that the risk of harm from Symbioflor 2 is low.
A randomised study involving around 300 adults suggested that Symbioflor 2 was effective for treating IBS. However, the study had weaknesses. Benefit has not yet been established in children with IBS.
Since the available data are not sufficiently robust for the CHMP to draw conclusions on how well Symbioflor 2 works and whether it is effective for any particular type of IBS, the CHMP has asked the company to carry out a well-designed study on effectiveness and safety among patients with different features of IBS (e.g. those with diarrhoea or with constipation as an important feature). Submission of the study report to national authorities will be a condition for maintaining Symbioflor 2’s marketing authorisation.
The company that markets Symbioflor 2 did not submit data to support its use in ‘functional gastrointestinal disorders’ and agreed to remove this use from the medicine’s authorisation.
The CHMP recommendation will now be sent to the European Commission for a legally binding decision that will be valid throughout the EU.
|EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome||(English only)||23/06/2017|
Latest News from
Christine Lagarde: How can a united Europe meet the challenges it faces today?24/01/2020 15:20:00
Opening remarks by Christine Lagarde, President of the ECB, during a dinner on "Uniting Europe" at the World Economic Forum
Artificial intelligence: EU must ensure a fair and safe use for consumers24/01/2020 14:20:00
MEPs want a strong set of rights to protect consumers in the context of artificial intelligence and automated decision-making.
Show us the money for new policy proposals, MEPs tell budget commissioner24/01/2020 13:20:00
During a debate with budget commissioner Johannes Hahn on 22 January, members of the Parliament’s negotiating team for the EU's next long-term budget expressed concern that the Commission’s budget proposal for how the EU should spend its money the next seven years no longer adds up.
The EESC bids farewell to its UK members with the promise of maintaining close ties with UK civil society24/01/2020 12:20:00
The European Economic and Social Committee (EESC) paid tribute to its British members on 22 January 2020 at the last plenary session they will attend before the UK leaves the EU on 31 January.
Brexit: the Withdrawal Agreement passes the first European Parliament test24/01/2020 11:20:00
The Constitutional Affairs Committee agreed on Thursday to recommend that the EP plenary should approve the UK withdrawal terms.
Mobility package: Transport Committee backs deal with EU Ministers23/01/2020 14:20:00
The revised rules for posting of drivers, drivers’ rest times & better enforcement of cabotage rules aim to put an end to distortion of competition in the road transport sector and provide better rest conditions for drivers.
French and Dutch migrant smuggling ring halted with 23 arrests23/01/2020 12:20:00
In a joint action by French & Dutch authorities, 23 persons have been arrested on suspicion of facilitating the illegal transport of approximately 10 000 Kurdish migrants to the UK in refrigerated lorries & small rubber boats, starting from various parking areas in France.
No more lead in PVC to protect public health, Environment Committee says22/01/2020 15:25:00
To protect human health and the environment, the Environment Committee objected on Tuesday to a EC proposal allowing lead in recycled PVC.
Future of Europe: debate on reforming the EU22/01/2020 13:25:00
The Conference on the future of Europe is a new initiative looking at what legal changes are needed to better prepare the EU for the future. It is expected to run for two years, involving a cross-section of society to give people the chance to contribute.
Canada – edible cannabis products may now be sold in Canada22/01/2020 09:25:00
From 16 December 2019, edible cannabis products are permitted to be sold in Canada. These must comply with new regulations for edible, inhalable & topical products, designed to reduce the risk of accidental consumption or overconsumption.